Choose Your News
Loading...
Thumbnail
Roche's acquisition of Foundation Medicine was a big event earlier in 2018. The availability of a liquid biopsy platform has the potential to change oncology... [Read More]
Tocagen has yet to release results from its pivotal glioblastoma study. However, faster-than-expected enrollment in this study indicates serious urgency on the... [Read More]
The prospects of imetelstat in myeloproliferative diseases have been discussed ad nauseum. In the absence of further evidence, it seems likely that they will be... [Read More]
Thumbnail
AbbVie and partner Janssen quietly announced an important submission. The implications for CLL management are clear, and they signal a tighter weaving of one of... [Read More]
Thumbnail
Merck's application for first-line pembrolizumab in a wider patient population has now been accepted. If approved, it could change the dimension of the market f... [Read More]
Thumbnail
The renal cell cancer space has been highly competitive, with substantial disruption coming in just the past few years. Pfizer looks to maintain its grip... [Read More]
Thumbnail
With a PDUFA in lung cancer coming up, Pfizer has a seemingly tall uphill climb to face its competition. There remain possible scenarios where Pfizer's... [Read More]
Thumbnail
Loxo is an important success story of our time, making big gains for investors and the oncology community alike. More breakthroughs give the company an... [Read More]
Chi-Med got big news about its anti-angiogenic drug in China. Approval here puts the company in line to compete with the likes of Bayer. Rather... [Read More]
Advaxis announced a new partnership for an undisclosed amount of money. Cash concerns continue to plague the company, but this provides a valuable signal moving... [Read More]
Karyopharm has built its initial momentum on development for heavily pretreated myeloma. At an upcoming meeting, we will get a better look at how its... [Read More]
Clovis has been a third-place player in the PARP space for a while now. Recent news signals a turn toward a novel direction for this... [Read More]
New approvals for CAR-T cell juggernauts should rekindle an important conversation about how these therapies will expand their sales. Although they've started m... [Read More]
Bristol-Myers has finally gotten out a new application for approval for its relatively small Empliciti franchise. This approval has important implications for t... [Read More]
Recent news about CheckMate 9ER has important implications for the renal cell carcinoma field. By joining forces, Bristol-Myers and Exelixis are offering a syne... [Read More]
Eisai and Merck's liver cancer partnership pays off. Brainsway gets its way for OCD. Evoke Pharma looks for its day with the FDA. [Read More]
Adaptimmune has several T-cell receptor projects currently being developed in-house. A recent licensing arrangement with a big pharma has seriously de-risked it... [Read More]
CytoDyn gives a look at a potential future direction for its CCR5 antibody. Adaptimmune marches forward in its MAGE study. Actinogen presses on through a... [Read More]
AVEO partner moves forward with a HER3 treatment in China. Motif Bio gets their priority day with the FDA. Realm Therapeutics crashes on bad dermatitis... [Read More]
Stemline is looking forward to their first drug approval in cancer. The first area of interest is an unmet need, but it is also a... [Read More]
Loading...
Preview